Overview

Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer

Status:
Completed
Trial end date:
2018-07-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerance of entinostat administered orally as a single agent in a weekly dosing schedule. Additionally, this study will characterize the pharmacokinetics parameters in Chinese postmenopausal women with advanced breast cancer. And to define the profile of adverse events, including laboratory parameters in these subjects
Phase:
Phase 1
Details
Lead Sponsor:
EddingPharm Oncology Co., LTD.
Taizhou EOC Pharma Co., Ltd.
Treatments:
Entinostat
Exemestane
Histone Deacetylase Inhibitors